Left ventricular ejection fraction, or LVEF, is the percentage of blood the left ventricle pumps out with each contraction, and it remains the workhorse metric of cardiac function worldwide. In the transplant arena, most research attention has focused on the donor heart’s LVEF at the time of procurement. Curiously, that early measurement has proven surprisingly uninformative: donor hearts with impaired function at procurement often recover fully, a phenomenon attributed in part to the catecholamine surge that follows donor brain death, which can temporarily stun the ventricle. When ischemic time is kept under four hours, recipients of such hearts generally fare well. What has been far less clear is whether the LVEF recorded a year after transplantation, once the dust of surgery has settled, carries any prognostic weight.

To answer that question, researchers led by Ahad Firoz of the University of California, Davis Medical Center, together with colleagues at UC Davis and the Lewis Katz School of Medicine at Temple University, analyzed adult first-time isolated orthotopic heart transplant recipients transplanted between January 2010 and September 2022 who survived to their one-year follow-up. Recipients with missing LVEF data at that visit were excluded, leaving a final cohort of 23,629 patients. The investigators deliberately chose the one-year mark because ventricular dysfunction related to procurement injury and acute postoperative graft changes is expected to have resolved by then, making any residual dysfunction a meaningful signal rather than a transient artifact. Follow-up data collected between 0.75 and 1.25 years after transplant were used, and patients were tracked until October 2023.

The cohort was stratified into four clinically grounded categories: preserved LVEF of 50 percent or above, which served as the reference group and comprised 96.4 percent of recipients; mildly reduced LVEF of 40 to 49 percent; moderately reduced LVEF of 30 to 39 percent; and severely reduced LVEF below 30 percent. Mean LVEF values in these groups were 61.1, 44.3, 34.3, and 21.6 percent respectively. The statistical architecture of the study was deliberately conservative. Four sequential models adjusted for an expanding set of covariables, culminating in a fully adjusted model that accounted for recipient demographics, functional status, comorbidities such as diabetes and hepatitis C, rejection episodes, hospitalizations, dialysis requirement, and an extensive panel of donor characteristics including donor LVEF at procurement, ischemic time, donor-recipient predicted heart mass ratio, and HLA-DR and CMV mismatch.

The headline result was a graded, dose-response relationship between one-year LVEF and mortality. Across 1,802 deaths recorded during follow-up, three-year survival from the baseline exam fell from 91.0 percent in the preserved group to 84.7 percent with mildly reduced, 74.3 percent with moderately reduced, and 68.5 percent with severely reduced function. In the fully adjusted Cox regression models, mildly reduced LVEF carried a 28 percent higher hazard of all-cause mortality (hazard ratio 1.28, p = 0.011), moderately reduced LVEF a 90 percent higher hazard (HR 1.90, p < 0.001), and severely reduced LVEF more than double the hazard (HR 2.06, p = 0.002). Cardiovascular mortality followed an even steeper gradient, with hazard ratios of 1.98, 3.17, and 4.54 across the three reduced categories, meaning patients with severely reduced function faced a 354 percent greater risk of dying from cardiovascular causes than those with preserved function.

Beyond survival, the study broke new methodological ground by applying a competing-risk framework to cardiac allograft vasculopathy, the progressive, atherosclerosis-like narrowing of the transplanted heart’s coronary arteries that is among the most feared late complications of transplantation. Using cumulative incidence functions, Gray’s test, and Fine-Gray subdistribution hazard models, with death treated as a competing event, the team found that the median time to CAV after the first annual visit shrank progressively as LVEF declined, from 2.9 years in the preserved group to just 1.2 years in the severely reduced group. After full adjustment, the subdistribution hazard ratios for CAV were 1.28, 1.57, and 1.65 for the mildly, moderately, and severely reduced groups respectively. This is the first report in the literature to assess CAV outcomes across LVEF groups using a competing-risk model, an approach that guards against overestimating risk when many patients die before vasculopathy can develop.

The web of associated morbidity extended well beyond the arteries. Recipients with reduced one-year LVEF experienced higher rates of hospitalization during follow-up, more frequent acute allograft rejection requiring treatment, and greater incidence of both early postoperative kidney injury necessitating dialysis and chronic kidney failure requiring dialysis. New-onset diabetes after transplantation was also more common, affecting 9.7 percent of recipients with reduced LVEF compared with 6.7 percent of those with preserved function. At the two-year follow-up, the differences persisted or widened: only 37.8 percent of patients who had severely reduced LVEF at one year retained preserved function at two years, compared with 97.4 percent of the preserved group, and re-transplantation rates climbed from 1.0 percent in the preserved group to 8.2 percent in the severely reduced group.

The authors propose a plausible biological narrative linking these findings, while cautioning that causality cannot be established from retrospective registry data. Maladaptive processes that predispose the allograft to dysfunction may begin early after surgery, triggering a cascade: reduced cardiac output diminishes renal perfusion, fostering a cardiorenal-like syndrome and dysregulation of the renin-angiotensin-aldosterone system; rejection episodes prompt escalating doses of nephrotoxic immunosuppressants, further injuring the kidneys and promoting new-onset diabetes; and chronic or recurrent rejection, particularly the poorly understood antibody-mediated form, drives the progression from acute graft dysfunction to vasculopathy. Each of these complications, in turn, is independently associated with mortality, which may partly explain the striking survival gradient observed. Consistent with this, functional status at one year and rejection within the first year were the strongest predictors of reduced LVEF in the study’s regression analyses.

The study has limitations inherent to its design. As a retrospective registry analysis, it cannot establish temporal sequence, and the granularity of OPTN data is constrained: the circumstances under which the one-year echocardiogram was obtained, whether routine screening or diagnostic work-up, are unknown, raising the theoretical possibility of ascertainment bias, which the authors mitigated by anchoring measurements to a strict window around the annual visit. Information on CAV severity was also unavailable beyond its presence. Nevertheless, the sheer scale and diversity of the cohort, spanning multiple centers across the United States in the modern era of transplantation, lend the findings considerable generalizability, and the study is by far the largest investigation to date of one-year LVEF after heart transplantation.

The clinical message is straightforward and potentially practice-changing. A single echocardiographic number obtained at the one-year visit, a test many centers already perform, appears to identify a high-risk minority of recipients who warrant intensified surveillance: screening for vasculopathy, close monitoring of renal function and glucose metabolism, vigilance for rejection, and timely escalation of therapy. Because advanced CAV has limited treatment options and re-transplantation carries substantial risk, early identification of patients on that trajectory could mean the difference between intervention while the graft is still salvageable and crisis management after irreversible decline. For the roughly one in twenty-five transplant recipients whose graft function has not normalized by the first anniversary, that routine ultrasound image may now be recognized as far more than a formality; it may be a forecast.

Subject of Research: Prognostic value of one-year left ventricular ejection fraction after heart transplantation

Article Title: Prognostic implications of one-year left ventricular systolic function after heart transplantation

Article References: Firoz, A., Ebong, I., Cadeiras, M., Zhao, H., & Jimenez, S. (2026). Prognostic implications of one-year left ventricular systolic function after heart transplantation. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03022-1

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03022-1

Keywords: heart transplantation, left ventricular ejection fraction, cardiac allograft vasculopathy, graft rejection, mortality, OPTN registry, echocardiography, renal failure, prognosis, survival, immunosuppression, cardiology

The study’s design was meticulous, comparing the experiences of heart transplant recipients aged 18 and older, split between Medicaid and non-Medicaid cohorts. Researchers also evaluated the situation across two important timelines: before and after the implementation of the Affordable Care Act (ACA). This longitudinal examination revealed that patients insured through Medicaid exhibited a notably higher incidence of CAV over a period of 5 years, coinciding with inferior survival rates, particularly pronounced in the post-ACA period.

In a unique revelation, the findings of the study will be shared with the medical community at the Plenary Session of The Society of Thoracic Surgeons (STS) annual meeting, where it has been designated as the premier paper in the realm of perioperative and critical care. Sara Sakowitz, a medical student at the David Geffen School of Medicine at UCLA and the first author of the study, passionately outlined the crux of the concern. She stated, “CAV is a leading cause of morbidity and mortality following heart transplant. Our work demonstrates that socioeconomic disadvantage influences the risk of CAV in the months and years following this life-saving operation.”

While the ACA was designed to increase access to healthcare for many Americans, particularly those previously facing barriers due to lack of insurance, the study highlighted critical ongoing issues. Significant access challenges to necessary ongoing post-transplant care, affordable medication, and equitable, high-quality healthcare services remain pervasive, especially for Medicaid beneficiaries. This study conclusively presents evidence that despite expanded access via the ACA, hurdles still obstruct the path to optimal health outcomes for this vulnerable population.

The context becomes even richer when considering the role of treatment facilities in the outcomes of heart transplant patients. The research revealed that the risk associated with developing CAV was significantly reduced when patients received care from high-volume transplant centers. There was a stark contrast noted between the patient cohorts, as Medicaid recipients treated at non-high-volume centers faced a substantially greater risk of developing CAV. Conversely, those who received care at high-volume centers experienced risks akin to their non-Medicaid counterparts.

Understanding why patients at these high-volume centers display better outcomes is crucial. According to Peyman Benharash, a prominent cardiothoracic surgeon at UCLA Health and corresponding author of the study, several variables contribute to the favorable results witnessed in these specialized facilities. High-volume transplant centers are often home to expert teams that provide thorough and nuanced care plans tailored to individual patient needs, as well as robust support systems to aid recovery post-transplant.

These centers typically implement streamlined protocols to maintain consistent patient follow-up and guarantee access to essential medications. The comprehensive nature of care provided at these facilities—including coordinated efforts among healthcare teams that encompass physicians, nurses, pharmacists, and social workers—addresses both the medical and logistical challenges that patients face after surgery. This holistic approach to post-transplant care can lead to vastly improved outcomes, thereby substantially bolstering survival rates in patients.

This illuminating research serves as a clarion call to health systems and policymakers alike. It underscores the importance of addressing healthcare disparities rooted in socioeconomic status and insurance coverage. The findings advocate for targeted initiatives that would not only enhance access to high-quality healthcare services but also emphasize the need to equip community healthcare providers with the adequate resources necessary to deliver superior follow-up care to Medicaid patients.

As communities continue to grapple with the ramifications of health inequities, the findings of this study highlight a critical area of focus. The study not only provides an in-depth examination of current healthcare architectures but also delineates a pathway forward, urging systemic reforms aimed at enhancing care delivery for marginalized populations.

In summary, the interplay of socioeconomic status, insurance types, and post-transplant survival is complex and multifaceted. The research conducted by UCLA Health is a significant contribution to the discourse, focusing not just on numbers and statistics but on the human experience of heart transplantation. The disparities in outcomes faced by different patient cohorts based on their insurance status represent a systemic issue that requires urgent attention and innovative solutions.

In the grand scheme, improving the survival rates after heart transplants, especially in Medicaid recipients, requires a collective and concerted effort from the medical community, policymakers, and society as a whole. Understanding and addressing the definitive barriers to health equity can pave the way for a future where access to lifesaving treatments is truly available to all, regardless of socioeconomic background.

This study’s insights compel us to rethink strategies within our healthcare systems, pushing for a framework that prioritizes long-term patient care and diminishes the substantial risks linked with socioeconomic disadvantage. Implementing effective and equitable healthcare practices holds the promise of transforming the landscape of heart transplantation, fostering an environment where every individual has the opportunity to thrive post-surgery.

In conclusion, as we look forward to future advancements in transplant medicine and healthcare reform, it is imperative that we remain steadfast in our commitment to ensuring that the benefits of medical innovations are equitably distributed. The findings of this research not only shed light on critical disparities but also emphasize a shared responsibility to advocate for systemic change that serves those in most dire need.

Subject of Research: People
Article Title: Insurance-Based Disparities in Cardiac Allograft Vasculopathy Following Heart Transplantation Are Mediated by Care at High Volume Centers
News Publication Date: 24-Jan-2025
Web References:
References:
Image Credits:

Keywords: Cardiac Allograft Vasculopathy, Heart Transplantation, Socioeconomic Disadvantage, Medicaid, Healthcare Disparities, Survival Rates, High-Volume Transplant Centers.